1|Page
NR 607 FINAL EXAM 2026 / NR607 FINAL EXAM TEST
BANK NEWEST 2026 COMPLETE 300 QUESTIONS
AND CORRECT DETAILED ANSWERS|| VERIFIED
EXAM!!!|ALREADY GRADED A+||NEWEST UPDATE!!!
Which of the following are the most appropriate
pharmacologic management strategies for Skylar? Select
all that apply.
-continue risperidone 6 mg daily
-switch to aripiprazole 10 mg daily
-discontinue all antipsychotic medications
-prescribe valbenazine 40 mg daily - ANSWER--continue
risperidone 6 mg daily
-prescribe valbenazine 40 mg daily
Rationale: The most appropriate pharmacologic
management strategies for Skylar include continuing
risperidone 6 mg daily and prescribing valbenazine 40 mg
daily. Skylar has had good symptom control with
risperidone, but is experiencing symptoms of tardive
dyskinesia (TD) as evidenced by their AIMS score of 2; a
score of 2 or greater indicates TD. The APA recommends
treating moderate to severe TD symptoms associated with
,2|Page
antipsychotic therapy with a vesicular monoamine
transporter 2 (VMAT2) such as valbenazine
select the most appropriate ICD-10-CM codes for Skylar s
diagnosis. - ANSWER-F20.9 and G24.09
Rationale:
F20.9 Schizophrenia reflects Skylar's diagnosis that is
being treated at today's visit. On the ICD 10 webpage you
will see this synonym for the code: Schizophrenia in
remission.
G24.09 Other drug induced dystonia corresponds to the
new diagnosis- tardive dyskinesia.
Which of the following is the appropriate E/M code for this
visit?
99214
99213
99215
99205
99204
,3|Page
99203 - ANSWER-99215
Rationale: Skylar is an established client with one chronic
illness and a newly diagnosed second chronic illness who
needs prescription drug management. The new onset TD
warrants additional decision making. Therefore, Skylar's
visit qualifies as 99215: established client with high level
medical decision making.
Treatment-Resistant Depression (TRD) - ANSWER--
subset of MDD
-characterized by a lack of improvement despite the
provision of traditional and first-line therapeutic options
-criteria are 2+ unsuccessful trials of antidepressant
pharmacotherapy
-Inaccurate TRD diagnosis can lead to pseudo-resistance
• pts prescribed suboptimal med trials D/C their meds
because of adverse side effects
Management of TRD: Nutraceuticals - ANSWER--
adjunctive txs that may improve symptoms in clients with
TRD
-Omega-3 fatty acids
, 4|Page
• thought to tx depression by decreasing chronic
inflammation
-L-methylfolate
• active form of folate that crosses the blood-brain barrier
• reduces inflammation, reduces loss in gray matter, &
helps regulate serotonin, dopamine, & norepinephrine
-Other agents associated with improvement in depressant
symptoms:
• zinc
• magnesium
• coenzyme Q10
Management of TRD: Electroconvulsive Therapy (ECT) -
ANSWER--procedure that applies electrical stimulation to
the brain through transdermal electrodes attached to the
head to trigger seizure activity
• sedated under general anesthesia & given a muscle
relaxant during procedure
-Use limited to clients with:
• TRD
• elevated suicide risk
NR 607 FINAL EXAM 2026 / NR607 FINAL EXAM TEST
BANK NEWEST 2026 COMPLETE 300 QUESTIONS
AND CORRECT DETAILED ANSWERS|| VERIFIED
EXAM!!!|ALREADY GRADED A+||NEWEST UPDATE!!!
Which of the following are the most appropriate
pharmacologic management strategies for Skylar? Select
all that apply.
-continue risperidone 6 mg daily
-switch to aripiprazole 10 mg daily
-discontinue all antipsychotic medications
-prescribe valbenazine 40 mg daily - ANSWER--continue
risperidone 6 mg daily
-prescribe valbenazine 40 mg daily
Rationale: The most appropriate pharmacologic
management strategies for Skylar include continuing
risperidone 6 mg daily and prescribing valbenazine 40 mg
daily. Skylar has had good symptom control with
risperidone, but is experiencing symptoms of tardive
dyskinesia (TD) as evidenced by their AIMS score of 2; a
score of 2 or greater indicates TD. The APA recommends
treating moderate to severe TD symptoms associated with
,2|Page
antipsychotic therapy with a vesicular monoamine
transporter 2 (VMAT2) such as valbenazine
select the most appropriate ICD-10-CM codes for Skylar s
diagnosis. - ANSWER-F20.9 and G24.09
Rationale:
F20.9 Schizophrenia reflects Skylar's diagnosis that is
being treated at today's visit. On the ICD 10 webpage you
will see this synonym for the code: Schizophrenia in
remission.
G24.09 Other drug induced dystonia corresponds to the
new diagnosis- tardive dyskinesia.
Which of the following is the appropriate E/M code for this
visit?
99214
99213
99215
99205
99204
,3|Page
99203 - ANSWER-99215
Rationale: Skylar is an established client with one chronic
illness and a newly diagnosed second chronic illness who
needs prescription drug management. The new onset TD
warrants additional decision making. Therefore, Skylar's
visit qualifies as 99215: established client with high level
medical decision making.
Treatment-Resistant Depression (TRD) - ANSWER--
subset of MDD
-characterized by a lack of improvement despite the
provision of traditional and first-line therapeutic options
-criteria are 2+ unsuccessful trials of antidepressant
pharmacotherapy
-Inaccurate TRD diagnosis can lead to pseudo-resistance
• pts prescribed suboptimal med trials D/C their meds
because of adverse side effects
Management of TRD: Nutraceuticals - ANSWER--
adjunctive txs that may improve symptoms in clients with
TRD
-Omega-3 fatty acids
, 4|Page
• thought to tx depression by decreasing chronic
inflammation
-L-methylfolate
• active form of folate that crosses the blood-brain barrier
• reduces inflammation, reduces loss in gray matter, &
helps regulate serotonin, dopamine, & norepinephrine
-Other agents associated with improvement in depressant
symptoms:
• zinc
• magnesium
• coenzyme Q10
Management of TRD: Electroconvulsive Therapy (ECT) -
ANSWER--procedure that applies electrical stimulation to
the brain through transdermal electrodes attached to the
head to trigger seizure activity
• sedated under general anesthesia & given a muscle
relaxant during procedure
-Use limited to clients with:
• TRD
• elevated suicide risk
